Red-bellied black snake venom toxins (RBBS venom)

The venom toxins of Pseudechis porphyriacus, commonly known as the Red-bellied Black Snake, consist of a diverse array of bioactive proteins including phospholipases A2 (PLA2), cysteine-rich secretory proteins (CRISPs), and procoagulants (UniProt, 2023). The most significant clinical effects are mediated by PLA2 isoforms like pseudexin, which cause systemic myolysis (muscle breakdown) and inhibit blood coagulation by interfering with the prothrombinase complex (Churchman et al., 2010). Unlike many other Australian elapids, P. porphyriacus envenomation rarely results in significant neurotoxicity in humans, though its toxins, such as pseudechetoxin, can block cyclic nucleotide-gated channels (Brown et al., 2003). Management of envenomation involves the use of CSL Black Snake Antivenom or Tiger Snake Antivenom, which provide neutralizing antibodies against the venom's enzymatic and non-enzymatic components (Toxinology.com). These toxins are also of interest in research for their ability to modulate ion channels and blood clotting pathways, potentially serving as leads for novel therapeutic agents. Overall, the venom represents a complex pharmacological cocktail that targets multiple physiological systems in prey and human bite victims.

Other names

Pseudechis porphyriacus venomPseudexinPseudechetoxinPseudechinRed-bellied black snake toxins

Neutralization of venom proteins via antibody binding (antivenom therapy)